Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrx’ ANDA Approvals On Hold Pending Resolution Of Manufacturing Issues

This article was originally published in The Pink Sheet Daily

Executive Summary

The company has been placed in “Official Action Indicated” status following an FDA inspection that resulted in a “Form 483.”

You may also be interested in...



Watson Integration Of Andrx Underway With 66 Combined ANDAs Pending

With acquisition of Andrx finalized, Watson now has three business divisions: Brand, Generic and Anda distribution.

Andrx’ Declining Revenue Reflects Cost Of Investments

The company says its decline in total revenues is reflective of its continued development of manufacturing processes and facilities.

Andrx’ Declining Revenue Reflects Cost Of Investments

The company says its decline in total revenues is reflective of its continued development of manufacturing processes and facilities.

Related Content

Topics

UsernamePublicRestriction

Register

PS062982

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel